Onkologie. 2010:4(4):270-276

Clinical experience with erlotinib treatment in patients with advenced non-small cell lung cancer

Marcela Tomíšková1, Jana Skřičková1, Michal Štícha2
1 Klinika nemocí plicních a tuberkulózy ve Fakultní nemocnici v Brně, Bohunicích
2 Lékařská fakulta Masarykovy univerzity v Brně

Erlotinib is one of the peroral low molecular-weight tyroxine-kinase inhibitors used in the treatment of patiens with advanced nonsmall

cell lung cancer (NSCLC) in Czech Republic. In addition to theoretic data about its mechanism and characteristic we concern

with group of 170 patiens with advanced NSCLC treated with erlotinib from the year 2005 in our department. We compare our

knowledges and results of treatment with statistical data published from another oncological center from Czech Republic within the

framework of Tarceva Register.

Keywords: erlotinib, cell targeted therapy, advanced non-small cell lung cancer, Epidermal Growth Factor Receptor

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomíšková M, Skřičková J, Štícha M. Clinical experience with erlotinib treatment in patients with advenced non-small cell lung cancer. Onkologie. 2010;4(4):270-276.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Skřičková J, et al. Bronchogenní karcinom In: Adam Z, Vorlíček J, Vaníček J, a kol. Diagnostické a léčebné postupy u maligních chorob, Praha, Grada Publishing, 2002: 33-53.
    2. Zatloukal P, Petruželka L. Karcinom plic, Praha, Grada 2001.
    3. Ginsberg RJ. Lung Cancer, London, BC Decker Hamilton, 2002.
    4. Bunn PA, Kelly K. New combination in the treatment of Lung Cancer, A Time of Optimism, Chest 2000; 117: 138S-143S. Go to original source... Go to PubMed...
    5. Klener P. Některé nové možnosti v protinádorové léčbě, přednáška laureáta, ,Staškovy ceny" za rok 2002, Český Krumlov 2002.
    6. Erlotinib - jedna z možností léčby nemalobuněčného karcinomu plic ovlivněním receptoru epidermální růstový faktor, Remedia, 2005.
    7. Pesek M, Krejci J, Skrickova J, Zatloukal P, Kolek V, Salajka F, Koubkova L, Sixtova D, Petruzelka L, Roubec J, Vyzula R, Pavlik T. Erlotinib therapy in non small cell lung cancer patients-survival of, ,poor prognosis patients". Journal of Thoracic Oncology 2009; 4(3 suppl 1): S704.
    8. Shepherd F, Pereira J, Ciuleanu E, et al. Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patiens treated with erlotinib in National Cancer Institute of Canada. Clinical trials Group (NIC CTG) trial BR. 21, Proc Am Soc Clin Oncol 2004 (post meeting edition), 23, 14S (Abstrakt 7022). Go to original source...
    9. Stinchcombe TE, Socinski MA. Gefitinib in advanced Non small Cell Lung Cancer: Does it deserve a Second Chance? The Oncologict 2008; 13: 933-944. www.The Oncologist.com. Go to original source... Go to PubMed...
    10. Felip E, RojoF, Keller A, et al. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer, SCO 2005, abstrakt 7100. Go to original source...
    11. Shepherd F, Pereira J, Ciuleanu E, et al. National Cancer Institute of Canada. Clinical trials Group: A randomized Placebo Controlled Study of Erlotinib (OSI-774,Tarceva) versus Placebo in Patiens with Incurable Non-SmallCell Lung Cancer Who Failed Standart Therapy for Advanced or metastatic Disease, ASCO 2004.
    12. Skřičková J, Pešek M, Zatloukal P, Kolek V, Koubková L, Salajka F, Zemanová M, Tomíšková M, Sixtová D, Pavlík T. Erlotinib (Tarceva(R)) in patients with non-small-cell lung cancer (NSCLC): results on 394 patients from Tarceva Register of Czech Republic. Journal of Thoracic Oncology 2009; 4(3 suppl 1): S714.
    13. Skřičková J, Pešek M, Zatloukal P, Kolek V, Koubková L, Salajka Fr, Štícha M, Tomíšková M, Kadlec B. Erlotinib in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): Results on 973 patients from Tarceva Register of Czech Republic. Journal of Thoracic Oncology 2010; 5(5 suppl. 1): S88-S89.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.